Background SGLT2 inhibition decreases albuminuria and reduces the risk of kidney disease
progression in patients with type 2 diabetes. These benefits are unlikely to be mediated by …

Background Reductions in albuminuria are associated with a subsequent lower risk of
kidney failure in patients with chronic kidney disease. The SGLT2 inhibitor dapagliflozin …

Background In patients with type 2 diabetes, intensive glucose control can be renoprotective
and albuminuria-lowering treatments can slow the deterioration of kidney function. We …

Background Dapagliflozin reduced the risk of kidney failure in patients with chronic kidney
disease with and without type 2 diabetes in the DAPA-CKD trial. In this pre-specified …

Aims Dapagliflozin is a selective inhibitor of sodium glucose co‐transporter 2 (SGLT2). This
study assessed the efficacy and safety of dapagliflozin 10 mg vs placebo in patients with …

In patients with diabetes, glycemic improvement by sodium-glucose cotransporter-2
inhibition depends on the kidney's ability to filter glucose. Dapagliflozin, a sodium-glucose …

Background The sodium–glucose co-transporter 2 inhibitor dapagliflozin decreases
haemoglobin A1c (HbA1c), body weight, blood pressure (BP) and urinary albumin …

Background Patients with chronic kidney disease have a high risk of adverse kidney and
cardiovascular outcomes. The effect of dapagliflozin in patients with chronic kidney disease …

Background Sodium-glucose co-transporter-2 (SGLT2) inhibitors have shown beneficial
effects on renal outcomes mainly in patients with established atherosclerotic cardiovascular …

Abstract Background The Dapagliflozin and Prevention of Adverse outcomes in Chronic
Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the effect of the …